Despite A Third Failure, Merck KGaA And GSK Won’t Give Up On Bintrafusp Yet
More Read-Outs To Come
After three failures in quick succession, Merck needs to see a win in one of its many remaining Phase II trials.
You may also be interested in...
GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.